Company intelligence / Profile preview

Pulmokine

USA

Ownership: Private
Development stage: Other

Overview

Pulmokine developed seralutinib, an inhaled small molecule PDGFR inhibitor. The program was licensed to Gossamer Bio, advanced to Phase 3 for pulmonary arterial hypertension, and subsequently acquired by XOMA Royalty in 2024. Clinical Phase 3 readout is expected Q4 2025, with strong mechanistic rationale for PAH and potential in other cardio-respiratory diseases[2][3][4][5].

Therapeutic areas: Cardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Gossamer BioChiesi Farmaceutici

Beyond the preview

Go deeper on Pulmokine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmokine.

Explore the full profile